🇺🇸 FDA
Pipeline program

AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CEFEPIME , CEFOTAXIME, SPIRAMYCIN , PIPERACILLIN AND BETA-LACTAMASE INHIBITOR

APHP210085

Approved small_molecule active

Quick answer

AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CEFEPIME , CEFOTAXIME, SPIRAMYCIN , PIPERACILLIN AND BETA-LACTAMASE INHIBITOR for EA-COPD (with mechanical ventilation, invasive or non-invasive, or high-flow nasal oxygen therapy). is a Approved program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
EA-COPD (with mechanical ventilation, invasive or non-invasive, or high-flow nasal oxygen therapy).
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials